REFERENCE

1. Tuberculosis (TB). World Health Organization. 2018 [cited 6 November

2018]. Available from:
http://www.who.int/news-room/fact-sheets/detail/tuberculosis
2. Tuberculosis (TB). Cdc.gov. 2018 [cited 6 November 2018]. Available
from: https://www.cdc.gov/tb/worldtbday/history.htm
3. Mandell, G., Bennett, J. and Dolin, R. (2010). Mandell, Douglas, and
Bennett's principles and practice of infectious diseases. Philadelphia, PA:
Churchill Livingstone/Elsevier, p.250.
4. Rieder, H., Chiang, C., Gie, R., Enarson, D. and Crofton, J.
(2009). Crofton's clinical tuberculosis. 3rd ed. pp.4-5.
5. Frieden TR, Sterling TR, Munsiff SS, Watt CJ, Dye C. Tuberculosis.
Lancet.2003;362: 887-899.
6. Jensen PA, Lambert LA, Iademarco MF, Ridzon R; Centers for Disease
Control and Prevention. Guidelines for preventing the transmission of
Mycobacterium tuberculosis in health-care settings, 2005. MMWR
Recomm Rep.2005;54(RR-17):1-141.
7. Porth CM. Alterations in respiratory function: respiratory tract infections,
neoplasms, and childhood disorders. In: Porth CM, Kunert MP.
Pathophysiology: Concepts of Altered Health States.Philadelphia, PA:
Lippincott Williams & Wilkins; 2002:615-619.
8. Van Crevel R, Ottenhoff THM, van der Meer JWM. Innate immunity to
Mycobacterium tuberculosis. Clin Microbiol Rev.2002;15: 294-309.
9. Dheda, K, Booth H, Huggett JF, et al. Lung remodeling in pulmonary
tuberculosis. J Infect Dis.2005;192:1201-1210.
10. Dheda, K, Booth H, Huggett JF, et al. Lung remodeling in pulmonary
tuberculosis. J Infect Dis.2005;192:1201-1210.
11. Ait-Kahed N, Alacron E, Armengol R, Bissell K, Boillot F, Caminero J A,
Chiang C-Y, Clebenbergh P, Dlodlo R, Enarson D A, Enarson P, Fujiwara
P I, Harries A D, Heldal E, Hinderaker S G, Lienhardt C, Monedero I,
Rieder HL, Rusen I D, Trebucq A, Van Deun A, Wilson N. Management
 of Tuberculosis: a guide to the essentials of good practice. Paris, France:
International Union Agaunst Tuberculosis and Lung Disease. 2010. pp.27-
38
12. Seung KJ, Keshavjee S, Rich ML. Drug-Resistant Tuberculosis. Cold
Spring Harb Perspect Med. 2015.
13. WHO. Treatment of Tuberculosis Guidelines 4th Edition. 2009.
14. Health Department Republic of South Africa. National Tuberculosis
Mangement Guidelines . 2014 .pp.43
15. WHO. (2010). Multidrug and extensively drug-resistant TB (M/XDR-TB).
Geneva, Switzerland: World Health Organization.
16. Tbfacts.org. (2018). Multi Drug Resistant TB - What is MDR, statistics,
treatment. [online] Available at: https://www.tbfacts.org/multi-drug-
resistant-tb/ [Accessed 8 Nov. 2018].
17. Dodd, P., Sismanidis, C. and Seddon, J. (2018). Global burden of drug-
resistant tuberculosis in children: a mathematical modelling study.
18. Munita J M, Arias C A. Mechanisms of Antibiotic Resistance. Microbiol
Spectr. 2016;4(2):10.1128/microbiolspec.VMBF-0016-2015.
19. Bhunia S, Sarkar M, Banerjee A, Giri B. An update on pathogenesis and
management of tuberculosis with special reference to drug resistance.
Asian Pacific Journal of Tropical Disease. 2015;5(9):673-686.
20. Davies J, Davies D. Origins and evolution of antibiotic
resistance. Microbiol Mol Biol Rev. 2010;74(3):417-33.
21. Millard J, Ugarte-Gil C, Moore D. Multidrug resistant tuberculosis. BMJ.
2015;350(feb26 10):h882-h882. doi:10.1136/bmj.h882
22. Raviglione M. Tuberculosis. New York: Informa Healthcare; 2010.
23. Dheda K, Gumbo T, Maartens G et al. The epidemiology, pathogenesis,
transmission, diagnosis, and management of multidrug-resistant,
extensively drug-resistant, and incurable tuberculosis. The Lancet
Respiratory Medicine. 2017;5(4):291-360. doi:10.1016/s2213-
2600(17)30079-6
24. Valafar F. Pathogenesis of multi drug-resistant and extensively drug-
resistant tuberculosis as a determinant of future treatment success. Int J
 Mycobacteriol. 2016;5:S64-S65. doi:10.1016/j.ijmyco.2016.11.017
25. Joon D, Nimesh N, Nimesh M. Clinical manifestations of tuberculosis.
Voyager. 2017 Jun;8(1):37-46.
26. Knechel NA. Tuberculosis: pathophysiology, clinical features, and
diagnosis. Critical Care Nurse. 2009 April;29(2):34-43.
27. Lee SH. Diagnosis and treatment of latent tuberculosis infection. Tuberc
Respir Dis (Seoul). 2015 Apr;78(2):56-63.
28. CDC. Basic tb facts: signs & symptoms [Online]. CDC; 2016 [updated
2016 Mar 17; cited 2018 Nov 6]. Available from:
https://www.cdc.gov/tb/topic/basics/signsandsymptoms.htm
29. Polena H, Boudou F, Tilleul S, Dubois-Colas N, Lecointe C,
Rakotosamimanana N, et al. Mycobacterium tuberculosis exploits the
formation of new blood vessels for its dissemination. Sci Rep [Internet].
2016 Sep;6:33162. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/27616470 DOI: 10.1038/srep33162
30. Fontanilla JM, Barnes A, von Reyn CF. Current diagnosis and
management of peripheral tuberculous lymphadenitis. Clin Infect Dis
[Internet]. 2011 Sep;53(6):555-62. Availbable from:
https://www.ncbi.nlm.nih.gov/pubmed/21865192 DOI: 10.1093/cid/cir454
31. Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR.
Epidemiology of extrapulmonary tuberculosis in the united states, 1993-
2006. Clin Infect Dis [Internet]. 2009 Nov;49(9):1350-7. Available from:
https://www.ncbi.nlm.nih.gov/pubmed/19793000 DOI: 10.1086/605559
32. Micheletti VCD, Kritski AL, Braga JU. Clinical features and treatment
outcomes of patients with drug-resistant and drug-sensitive tuberculosis: a
historical cohort study in porto alegre, brazil. PLoS ONE [Internet]. 2016
Aug;11(8):e0160109. Available from: DOI:
10.1371/journal.pone.0160109
33. Gilpin C, Korobitsyn A, Weyer K. Current tools available for the
diagnosis of drug-resistant tuberculosis [Internet]. 2016 [cited 4 November
2018]. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5375090/
34. Migliori GB, Matteelli A, Cirillo D. Diagnosis of mutrigrug-resistant
tuberculosis and extensive drug-resistant tuberculosis: Current standards
and challenges [Internet]. 2008 [cited 4 November 2018]. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2605858/
35. Seung KJ, Keshavjee S, Rich ML. Multidrug-Resistant Tuberculosis and
Extensively Drug-Resistant Tuberculosis [Internet]. 2015 [cited 4
November 2018]. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4561400/
36. Kaijin W, Sheng B, Zhongkang J. Distinguishing Nontuberculous
Mycobacteria from Multidrug-Resistant Mycobacterium tuberculosis,
China [Internet]. 2014 [cited 4 November 2018]. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4036753/
37. Chhabra N, Aseri ML, Dixit R, Gaur S. Pharmacotherapy for multidrug
resistant tuberculosis. J Pharmacol Pharmacother. 2012;3(2).
doi:10.4103/0976-500X.95502.
38. Seung KJ, Keshavjee S, Rich ML. Drug-Resistant Tuberculosis. Cold
Spring Harb Perspect Med. 2015.
39. WHO. Treatment of Tuberculosis Guidelines 4th Edition. 2009.
40. Elmi O, Hasan H, Abdullah S, Mat Jeab M, BA Z, Naing N. Treatment
Outcomes of Patients with Multidrug-Resistant Tuberculosis (MDR- TB)
Compared with Non-MDR-TB Infections in Peninsular Malaysia.
Malaysian Journal of Medical Sciences. 2016;23(4):17-25.
41. Gadallah M, Mokhtar A, Rady M, El-Moghazy E, Fawzy M, Kandil S.
Prognostic factors of treatment among patients with multidrug-resistant
tuberculosis in Egypt. Journal of the Formosan Medical Association.
2016;115(11):997-1003.
42. Oliveira O, Gaio R, Villar M, Duarte R. Predictors of treatment outcome
in multidrug-resistant tuberculosis in Portugal: Table 1–. European
Respiratory Journal. 2013;42(6):1747-1749.
43. Chung-Delgado K, Guillen-Bravo S, Revilla-Montag A, Bernabe-Ortiz A.
Mortality among MDR-TB Cases: Comparison with Drug-Susceptible
Tuberculosis and Associated Factors. PLOS ONE. 2015;10(3):e0119332.
44. Keshavjee S, Farmer PE. 2012. Tuberculosis, drug resistance, and the
history of modern medicine. New Engl J Med 367: 931–936. 
45. Pomerantz BJ, Cleveland JC, Olson JK, Pomerantz M. 2001. Pulmonary
resection for multi-drug resistant tuberculosis. J Thorac Cardiovasc
Surg 121: 448–453.
46. Riyanto BS, Wilhan. 2006. Management of MDR TB Current and Future
dalam Buku Program dan Naskah Lengkap Konferensi Kerja Pertemuan
Ilmiah Berkala. PERPARI.